Aldeyra Therapeutics (ALDX) Non-Current Assets (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Non-Current Assets came in at $209262.0 in Q1 2026, down 55.18% YoY from $466942.0 in Q1 2025, and down 24.14% on a QoQ basis from $275861.0 in Q4 2025.
Aldeyra Therapeutics (ALDX) Non-Current Assets (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of Non-Current Assets data on file, last reported at $209262.0 in Q1 2026.
- Quarterly Non-Current Assets fell 55.18% year-over-year to $209262.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 38.28% YoY) and the FY2025 annual result came in at $275861.0, down 48.36% from the prior year.
- Non-Current Assets eased to $209262.0 in Q1 2026, from $275861.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $598589.0 in Q3 2024 to a low of $72233.0 in Q3 2023.
- A 5-year average of $335139.4 and a median of $337926.0 in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets plunged 65.37% — and 2024, when it jumped 728.69%.
- Tracing ALDX's Non-Current Assets over 5 years: stood at $268544.0 in 2022, then jumped by 92.36% to $516578.0 in 2023, then advanced by 3.41% to $534216.0 in 2024, then plunged by 48.36% to $275861.0 in 2025, then declined by 24.14% to $209262.0 in 2026.
- The last three Non-Current Assets figures came in at $209262.0 (Q1 2026), $275861.0 (Q4 2025), and $340977.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Aldeyra Therapeutics | 90.18 Mn | 90.18 Mn | - | 161,653.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 161,653.00 |
| Mar 31, 2026 | 209,262.00 |
| Dec 31, 2025 | 275,861.00 |
| Sep 30, 2025 | 340,977.00 |
| Jun 30, 2025 | 404,660.00 |
| Mar 31, 2025 | 466,942.00 |
| Dec 31, 2024 | 534,216.00 |
| Sep 30, 2024 | 598,589.00 |
| Jun 30, 2024 | 394,315.00 |
| Mar 31, 2024 | 455,946.00 |
| Dec 31, 2023 | 516,578.00 |
| Sep 30, 2023 | 72,233.00 |
| Jun 30, 2023 | 137,232.00 |
| Mar 31, 2023 | 201,572.00 |
| Dec 31, 2022 | 268,544.00 |
| Sep 30, 2022 | 208,603.00 |
| Jun 30, 2022 | 273,914.00 |
| Mar 31, 2022 | 337,926.00 |
| Dec 31, 2021 | 384,350.00 |
| Sep 30, 2021 | 445,621.00 |